Financials data is unavailable for this security.
View more
Year on year GenMont Biotech Inc 's revenues fell -13.71% from 368.55m to 318.02m. This along with an increase in selling, general and administrative costs has contributed to a reduction in net income from 56.98m to 32.99m, a -42.10% decrease.
| Gross margin | 66.92% |
|---|---|
| Net profit margin | 17.01% |
| Operating margin | 11.08% |
| Return on assets | 3.66% |
|---|---|
| Return on equity | 5.43% |
| Return on investment | 4.48% |
More ▼
Cash flow in TWDView more
In 2023, cash reserves at GenMont Biotech Inc fell by 78.09m. However, the company earned 34.60m from its operations for a Cash Flow Margin of 10.88%. In addition the company used 75.37m on investing activities and also paid 36.82m in financing cash flows.
| Cash flow per share | 1.52 |
|---|---|
| Price/Cash flow per share | 15.01 |
| Book value per share | 15.47 |
|---|---|
| Tangible book value per share | 15.45 |
More ▼
Balance sheet in TWDView more
| Current ratio | 3.19 |
|---|---|
| Quick ratio | 2.65 |
| Total debt/total equity | 0.0819 |
|---|---|
| Total debt/total capital | 0.0694 |
More ▼
Growth rates in TWD
Year on year, both dividends per share and earnings per share excluding extraordinary items growth dropped -28.57% and -42.04%, respectively. Additionally when measured on a five year annualized basis, both dividend per share and earnings per share growth ranked below the industry average relative to its peers.
| Div yield(5 year avg) | 3.18% |
|---|---|
| Div growth rate (5 year) | -19.73% |
| Payout ratio (TTM) | 60.68% |
| EPS growth(5 years) | -19.13 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | 115.37 |
More ▼
